Episode Synopsis "Impact of COVID-19 to the Biotech and Diagnostics Industry"

The biotech and diagnostics industry have evolved significantly in the past few months with the impact of COVID. To get a better perspective of the state of this sector, I spoke with our biotech experts Caroline Popper, M.D. in the US and Bob Atwill in Australia.

Listen "Impact of COVID-19 to the Biotech and Diagnostics Industry"

More episodes of the podcast M&A Perspectives

• Leveraged Recapitalization as an Alternative To Selling
• The Oil & Gas Sector Rebounds In 2021
• Rebounding Economy Might Accelerate Your Business Sale Timeline
• 2021 Outlook: Private Capital Market
• M&A Insights from 10 Global Consulting Engineering Firms
• What is driving the US M&A Market?
• A Conversation with Accenture on the Current M&A Landscape
• Impact of COVID-19 to the Biotech and Diagnostics Industry
• Debt and Equity Market's Impact on Cross-border M&A
• How Has COVID-19 Impacted US Private Debt Availability?
• What can company owners do now, if they are thinking of selling later in the year?